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Endogenous proteomimetic sequences covalently coupled to cell penetrating peptides as 27 
sychnologically-organized bioportide constructs were successfully delivered to sperm cells to 28 
disrupt protein phosphatase 1 complexes and, consequently, reduce sperm motility. 29 
  30 
 3 
Abstract 31 
Objective: To design protein phosphatase 1 (PP1)-disrupting peptides covalently coupled to inert 32 
cell penetrating peptides (CPPs) as sychnologically-organized bioportide constructs as a strategy 33 
to modulate sperm motility. 34 
Design: Experimental study. 35 
Setting: Academic research laboratory. 36 
Patients/Animals: Normozoospermic men providing samples for routine analysis and Holstein 37 
Frisian bulls. 38 
Intervention(s): None. 39 
Main Outcome Measure(s): Effect of the bioportides on the activity and interactions of PP1γ2 40 
– a PP1 isoform expressed exclusively in testicular germ cells and sperm - and on sperm vitality 41 
and motility. 42 
Results:  PP1‐disrupting peptides were designed based on the sequences from (i) a sperm-specific 43 
PP1 interactor (A kinase anchor protein 4, AKAP4) and (ii) a PP1 inhibitor (protein phosphatase 44 
inhibitor 2, PPP1R2). Those sequences were covalently coupled to inert CPPs as bioportide 45 
constructs, which were successfully delivered to the flagellum of sperm cells to induce a marked 46 
impact upon PP1γ2 activity and sperm motility. Molecular modelling studies further facilitated 47 
the identification of an optimized PP1 binding sequence and enabled the development of a 48 
Modified Stop Sperm (MSS1) bioportide with reduced size and increased potency of action. 49 
Additionally, a bioportide mimetic of the unique 22-amino acid C-terminus of PP1γ2 accumulated 50 
within spermatozoa to significantly reduce sperm motility and further define the PP1γ2-specific 51 
interactome. 52 
Conclusion: These investigations demonstrate the utility of CPPs to deliver peptide sequences 53 
that target unique protein-protein interactions in spermatozoa to achieve a significant impact upon 54 
spermatozoa motility, a key prognostic indicator of male fertility. 55 
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Introduction 60 
The world’s population has been rising at an alarming level and is expected to reach 9.8 billion 61 
by 2050 (1). Between 2010-2014, and despite the currently available contraceptive methods, 62 
approximately 40% of all pregnancies worldwide were unintended (2). Compared with female 63 
contraceptive measures, male contraceptive options are few in number and underused (3). To 64 
date, the development of new male contraceptives has mostly focused upon hormonal modulation 65 
(4); however, the pharmaceutical industry has abandoned many of the investments in this field 66 
due to reports of severe side effects (5). Most non-hormonal approaches in research focus either 67 
on the suppression of spermatogenesis or reversible physical barriers (3). The mechanism of 68 
sperm motility acquisition in the epididymis constitutes an ideal target for a new male 69 
contraceptive, since only post-testicular sperm maturation is affected, allowing normal hormone 70 
and spermatozoa production to occur and drugs do not necessarily need to cross the blood-testes 71 
barrier. In addition, drugs targeting sperm motility might also have a faster onset of action, 72 
allowing for administration immediately before intercourse (6). 73 
The spermatozoon is virtually incapable of genetic expression. Any functional alteration (e.g. 74 
motility acquisition) in these cells depends on processes such as protein post-translational 75 
modifications (e.g. phosphorylation) (7). Protein phosphatase 1 (PP1) catalyses a considerable 76 
fraction of phosphoserine/threonine dephosphorylation reactions in eukaryotic cells and 77 
inhibition of its catalytic activity is essential for sperm motility acquisition and regulation (8–11). 78 
Smith et al showed immotile bovine caput epididymal sperm presented a two-fold higher activity 79 
of PP1 compared with fully mature motile sperm and that inhibition of PP1 by phosphatase 80 
inhibitors (calyculin A and okadaic acid) induced caput sperm motility (10,12). 81 
In mammals, PP1 is encoded by three different genes giving rise to PP1α, PP1β and PP1γ 82 
isoforms. After transcription, PP1γ undergoes tissue-specific splicing, originating a ubiquitous 83 
isoform, PP1γ1, and a testis- and sperm-specific isoform, PP1γ2, which localizes at the posterior 84 
and equatorial head regions and along the entire flagellum (11,13,14). The molecular difference 85 
between these two PP1γ isoforms resides in the carboxyl-terminus (C-terminus) (15). 86 
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Regulation of PP1 catalytic activity is mediated by forming holoenzymes with regulatory 87 
interactors of protein phosphatase one (RIPPOs, previously called PP1-interacting proteins - 88 
PIPs) (16–21). In mammalian sperm, protein phosphatase inhibitor 2 (PPP1R2), a PP1 inhibitor, 89 
is central in controlling PP1 activity and, consequently, motility (7).  In human mature sperm, 90 
part of the total PP1 population is bound to PPP1R2 and within these complexes PP1 is inactive 91 
(20). PPP1R2 is a highly intrinsically disordered protein that only acquires a defined structure 92 
when associated with PP1 (16,18,19). PPP1R2 contains two degenerated RVxF motifs (20,22). 93 
In mammalian sperm PP1γ2 appears to be the sole responsible for PP1 activity (10,11). and 94 
inhibition of PP1 by phosphatase inhibitors (calyculin A and okadaic acid) induces caput sperm 95 
motility (10).  96 
A kinase anchor protein 4 (AKAP4) is a sperm-specific protein, previously described as a PP1γ2 97 
interactor in human sperm (23) and associated with motility regulation (24). Male mice lacking 98 
AKAP4 are infertile, the motility of their sperm is poor, and the principal piece of the flagellum 99 
is morphologically and functionally abnormal (25). The Akap4 gene knockout mice are also 100 
characterized by a significant change in the activity and phosphorylation status of PP1γ2 (26).  101 
The interfaces between PP1γ2 and RIPPOs, such as PPP1R2 or AKAP4, represent an attractive 102 
target for pharmacological intervention to modulate PP1 and thus develop strategies to influence 103 
spermatozoa motility and male fertility. The binding of RIPPOs to PP1 is mediated by short amino 104 
acid (AA) motifs of which 10 have already been described and characterized (8,27,28). The most 105 
common PP1 binding motif, RVxF, is present in about 90% of all known RIPPOs and is thought 106 
to be the primary anchor point for subsequent interactions (27). The RVxF binding motif is a short 107 
linear motif that binds to the RVxF-binding site on PP1 and is unique to PP1 within the 108 
phosphoprotein phosphatase-like family (27,29). Currently only two drugs (salubrinal and 109 
trichostatin A) are known to modulate PP1 complexes (for review see (9)). In recent years, 110 
peptides have emerged as one of the important classes of therapeutic molecules but only a few in 111 
vitro studies have employed synthetic peptides (based on the RVxF motif) to disrupt PP1-RIPPOs 112 
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complexes (29–32). To date, modulation of spermatozoa physiology by synthetic peptides or 113 
small molecules that disrupt PP1 complexes has not been accomplished. 114 
CPPs, mostly polycationic sequences of 12-20 AA in length, represent a very promising 115 
intracellular delivery system to target protein-protein interactions (PPIs) (33,34). In 2015, Jones 116 
et al demonstrated that CPPs are able to translocate into human and bovine sperm cells without 117 
detrimental influence upon viability or motility (33). More recently, a novel genre of CPP, distinct 118 
from conventionally inert vectors, has been developed that possesses the dual features of both 119 
cellular penetration and biological activity. Termed bioportides, these proteomimetic CPPs may 120 
include sequences derived from functional protein domains (e.g. RVxF binding motif) to serve as 121 
potent and selective biological modulators of PPIs (35–37).  122 
In this study, we designed peptides mimetic of (i) the PP1 binding motif of human AKAP4, (ii) 123 
the PP1 binding motif of the human PPP1R2, and (iii) the unique 22-amino acid C-terminus of 124 
PP1γ2. These were covalently coupled to an inert CPP to form sychnologically-organized 125 
bioportide constructs with the aim of compromising PP1 interactions in intact spermatozoa. We 126 
rigorously evaluated the impact of these potential competitive bioportides on both PP1 activity 127 
and sperm motility. Additionally, we employed a bioportide (PP1γ2-CT) to characterize the 128 
PP1γ2 C-terminal interactome and identify proteins that specifically interact with the PP1γ2 129 
isoform. This approach clarified the potential mechanism of action of this bioportide to further 130 
define the unique role of this PP1 isoform in human sperm.   131 
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Methods 132 
Microwave-assisted solid phase peptide synthesis 133 
Peptide mimetic sequences employed in the construction of bioportides (Table 1) included: (a) A 134 
20 AA sequence from human AKAP4 including the PP1 binding motif (40KVICF44), AKAP433-52 135 
(GQQDQDRKVICFVDVSTLNV; AKAP4-BM). (b) An Ala-substituted homologue of AKAP43-136 
52 lacking the PP1 binding motif (GQQDQDRAAAAAVDVSTLNV; AKAP4-BMmut). (c) A 137 
19AA sequence from human PPP1R2 including an alternative PP1 binding motif (44KSQKW48), 138 
PPP1R236-54, (VDEELSKKSQKWDEMNILA; PPP1R2-BM). (d) A homologue of PPP1R236-54 139 
with a scrambled PP1 binding motif (VDEELSKQWKKSDEMNILA; PPP1R2-BMsc).  (e) The 140 
22 AA C-terminus of human PP1γ2, PP1γ2303-336, 141 
(KPNATRPVTPPRVASGLNPSIQKASNYRNNTVLY; PP1γ2-CT). (f) A shorter decapeptide 142 
homologue of AKAP433-52, YRSVITFVAV, designed by molecular modelling as an improved 143 
PP1 binding motif, was included as the N-terminus of MSS1. These endogenous sequences were 144 
covalently coupled to CPPs, penetratin or C105Y, as sychnologic bioportide constructs as 145 
indicated in Table 1. 146 
Employing previously described protocols (38), AKAP4-BM, AKAP4-BMmut, PPP1R2-BM, 147 
PPP1R2-BMsc and PP1γ2-CT were prepared by microwave-assisted solid phase peptide 148 
synthesis using a Discover SPS Microwave Peptide Synthesizer (CEM Microwave Technology 149 
Ltd, Buckingham, UK) with fibre optic temperature control. These peptides were synthesized (0.1 150 
mmol scale) using Rink amide MBHA resins pre-loaded with the first AA (AnaSpec, Inc., 151 
Cambridge Bioscience Ltd, Cambridge, UK) and employed a N-α-Fmoc protection strategy with 152 
HCTU activation. Deprotection with 7 ml of 20 % piperidine was performed for 3 min at 50 W/75 153 
°C A majority of AA coupling reactions were accomplished with a 4-fold molar excess of Fmoc-154 
protected AA with HCTU and diisopropylethylamine (DIPEA), molar ratio of 1:1:2 155 
(AA/HCTU/DIPEA), in 4 ml for 10 min at 25 W/75 °C. Arg coupling was performed in two 156 
stages: 30 min 0 W/∼25 °C followed by 5 min at 17 W/75 °C. To reduce racemization of Cys 157 
coupling conditions were 5 min at 0 W/∼25 °C followed by 6 min at 17 W/50 °C with the hindered 158 
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base collidine (TMP) at a molar ratio of 1:1:2 (AA/HCTU/TMP; (39)). Aspartimide formation 159 
was reduced by the substitution of piperidine for 5 % piperazine and 0.1 M 1-hydroxybenztriazole 160 
hydrate (HOBt) in the deprotection solution. MSS1 was synthesized on a fully automated CEM 161 
Liberty Blue machine using similar activation and deprotection strategies routinely monitored by 162 
determining the UV absorption at 301 nm of Dibenzofulvene-piperidine adducts as recently 163 
described in detail (40). 164 
Fluorescent peptides, to be used in cell imaging and quantitative uptake analyses, were 165 
synthesized by amino-terminal acylation with 6-carboxy-tetramethylrhodamine (TAMRA) 166 
(Novabiochem, Beeston, UK) as previously described (41). A biotinylated analogue of PP1γ2-167 
CT, to be used in co-immunoprecipitation assays, was also synthesized using similar methods to 168 
conjugate biotin (Sigma) to the N-terminal of PP1γ2-CT. All peptides were purified by semi-169 
preparative scale high-performance liquid chromatography and their predicted masses confirmed 170 
by mass spectrometry. 171 
 172 
Phosphatase activity assay 173 
A concentration range of commercial PPP1R2 (New England Biolabs, Herts, UK) was incubated 174 
with purified PP1γ2 (1:20; 1:200 and 1:2000) and either PPP1R2-BM or PPP1R2-BMsc for 30 175 
min (ratio of 1:200:0.5 of PPP1R2, PP1γ2 and peptides). PP1γ2 activity was measured over 30 176 
min, in 5 min intervals, using the SensoLyte® pNPP Protein Phosphatase Assay Kit 177 
*Colorimetric*(AnaSpec, Inc., Cambridge Bioscience Ltd, Cambridge, UK) and a PP1 specific 178 
assay buffer according to manufactures instructions. Negative control (only assay buffer) was 179 
included. Four replicas were performed. 180 
 181 
Semen samples analyses and processing 182 
This study was approved by the Ethics and Internal Review Board of the Hospital Infante D. 183 
Pedro E.P.E. (Aveiro, Portugal) (Process number:36/AO; Approved on 14 April 2015) and was 184 
conducted in accordance with the ethical standards of the Helsinki Declaration. Human semen 185 
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samples were obtained from a group of donors by masturbation into a sterile container. All donors 186 
signed informed consent allowing the samples to be used for scientific purposes. Basic semen 187 
analysis was performed according to World Health Organization (WHO) guidelines. Fresh semen 188 
from Holstein Frisian bulls was obtained from LusoGenes, LDA (Aveiro, Portugal). Semen was 189 
collected by artificial vagina and assessed by a certified veterinarian. 190 
Human and bovine spermatozoa were isolated and washed from seminal plasma by centrifugation 191 
(500 g for 5 min, 3 times) using ALLGrade Wash medium (LifeGlobal, Brussels, Belgium). 192 
Spermatozoa pellets were resuspended in medium to a final concentration of 20x106 cells/0.5 mL 193 
and incubated at 37 °C with 5 % CO2 until the appropriated treatments were added. 194 
 195 
Microscopic evaluation of the intracellular accumulation of the bioportides 196 
Isolated bovine and human spermatozoa (40x106 cells) were resuspended and incubated with 10 197 
μM tetramethylrhodamine (TAMRA)-labeled bioportides for 1 h at 37 °C in a humidified 198 
atmosphere of 5 % CO2. Cells were then washed three times (500 g for 5 min) in ALLGrade Wash 199 
medium (LifeGlobal, Brussels, Belgium). To determine whether the fluorescently labeled 200 
bioportides were merely surface associated, we divided the sperm cell population in two and used 201 
a trypsin incubation to remove any surface associated bioportides. In summary, 50% of the cells 202 
were set aside (20x106 cells) and fixed in 4 % paraformaldehyde (PFA) for 20 min. The other 203 
50% was incubated with 1 % (wt/vol) trypsin at 37 °C, collected by centrifugation at 3000 g, 204 
washed in ALLGrade Wash medium (LifeGlobal, Brussels, Belgium) and resuspended in 4 % 205 
PFA for 20 min. Fixed cells from each preparation were spread into coverslips and allowed to air 206 
dry. After mounting, slides were assessed by fluorescence microscopy (Imager.Z1, Axio-Cam 207 
HRm camera and AxioVision software, Zeiss, Jena, Germany). 208 
 209 
Comparative quantitative analyses of bioportide translocation 210 
The translocation efficacies of bioportides were determined by quantitative uptake analysis of 211 
fluorescently labeled peptides based upon the method previously described by Holm et al. (42). 212 
Isolated bovine and human spermatozoa were incubated with TAMRA-labeled bioportides at 37 213 
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°C in a humidified atmosphere of 5 % CO2. Cells were then washed four times with 200 µl of 214 
phosphate buffered saline (PBS) (600 g for 5 min), detached with 1 % (w/v) trypsin at 37 °C, 215 
collected by centrifugation at 3000 g and lysed in 300 μl 0.1 M NaOH for 2 h on ice. 250 μl of 216 
each sample cell lysate were transferred to a black 96-well plate and analysed using an Infinite® 217 
200 PRO (Tecan, Switzerland) (λAbs 544 nm/λEm 590 nm). 218 
 219 
Cell viability assays 220 
Bovine spermatozoa viability was evaluated using the Trypan Blue viability test (Fisher 221 
Scientific, Loures, Portugal) according to manufacturer’s guidelines. 200 sperm cells were 222 
counted per replicate using a Zeiss Primo Star microscope (Zeiss, Jena, Germany). Human 223 
spermatozoa viability was measured using the CellTiter 96® AQueous Non-Radioactive Cell 224 
Proliferation Assay (Promega, Madison, USA) according to manufacturer's guidelines. The 225 
reduction of tetrazolium compounds has previously been used as a reliable and rigorous 226 
assessment of spermatozoa viability (43).  227 
 228 
Motility assays 229 
Bovine and human sperm cells were diluted in medium to achieve a total volume of 500 µl, 230 
containing 20x106 sperm cells. Control samples included sperm cells in medium alone. The 231 
influence of bioportides upon sperm motility parameters was assessed using the Sperm Class 232 
Analyzer CASA System (Microptic S L, Barcelona, Spain) with SCA® v5.4 software. Samples 233 
and controls (2 µl) were loaded into individual chambers of Leja Standrat Count 8 chamber slide 234 
20 µm depth (Leja Products B. V., The Netherlands) (bovine) or Leja Standrat Count 4 chamber 235 
slide 10 µm depth (Leja Products B. V., The Netherlands) (human), which were pre-heated at 37 236 
°C. This temperature was maintained while at least 1000 sperm cells per measurement were 237 
evaluated. Each bioportide was tested on samples from 3 individual donors and all the conditions 238 
were performed in triplicate. 239 
 240 
Computer-assisted peptide design and optimisation 241 
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To support the design of chemically optimised bioportides, molecular dynamics simulations 242 
(MD) were initially used to characterise possible conformational preferences of the PP1γ2 protein 243 
target and of a prototypical binding sequence derived from AKAP4. PP1γ1 was retrieved from 244 
Protein Data Bank (PDB codes: 2O8G) and used as a target for peptide-binding since the crystal 245 
structure of PP1γ2 is not available. PP1γ1 is highly homologous to PP1γ2 and differs only by the 246 
lack of a long and disordered carboxyl tail, a structural feature expected to introduce a high level 247 
of noise in MD simulations. Further, the RVxF binding pocket of PP1γ1 and PP1γ2 are identical. 248 
The peptide sequence studied in isolation was AKAP4wt (QRKVICFVAV). Each MD was 249 
performed using the Amber 14 (44), suite of programs. The peptide and protein were simulated 250 
using ff14SB (45) force field and prepared with Leap to add missing hydrogen atoms and to 251 
generate a solvated system. The simulation box of explicit water molecules (TIP3P model) was 252 
extended up to 10 Å (PP1γ) or 12 Å (AKAP4 peptide), counter ions of Na+ were added to 253 
neutralize the system. The simulation started with an unrestrained minimization consisting of 254 
2500 steps followed by a minimization constrained at the Ca of 4000 steps. The minimized system 255 
was then equilibrated in two cycles at 300K: the first keeping the peptide under a restraint at Ca 256 
constant force of 500 kcal/mol/A^2 and the second equilibration with the release of the restraint 257 
for 5 ns. Simulations with constant temperature (298K), using the weak-coupling algorithm (46). 258 
The SHAKE algorithm was used to constrain all covalent bonds involving hydrogen atoms. The 259 
production runs for both the protein and the peptide were 500 ns long.  260 
For each system, a conformational cluster analysis using gromos algorithm was carried out using 261 
a cut-off of 0.2 nm (47). Each of the cluster centroids is used as a representative structure. The 262 
representative structures of the most populated clusters for the protein and the peptide were used 263 
as inputs for protein-peptide docking experiments using the GLIDE peptide-docking module of 264 
the MAESTRO suite of programs. The best solution was used for further refinement of the peptide 265 
sequence.   266 
Sequence optimisation for binding to PP1γ1 was carried out using PinaColada and PepCrawler. 267 
Briefly, the principle behind PinaColada lies on the optimisation of the initial peptide through the 268 
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ant-colony method (48). To refine the peptide with the highest inhibitory affinity the peptide 269 
conformation and free energy of the interaction with the receptor protein is predicted through the 270 
PepCrawler algorithm (49), a local docking algorithm for peptide-protein interactions. Five runs 271 
were performed from which the top 4 best performers were selected for further synthesis. This 272 
selection was based on the lowest energy and funnel which together provide both the best binding 273 
energy and binding affinity. 274 
MD simulation studies of PPP1R2-BM and scrambled and the 7 flanking AA were performed by 275 
the MD simulation package Amber v14 applying Amber-ff14SB force field (45). The two systems 276 
were solvated, in a simulation octahedral box of explicit water molecules (TIP3P model) (50), 277 
counter ions were added to neutralize the system and periodic boundary conditions imposed in 278 
the three dimensions (12 Aº). After minimizations, systems were subjected to an equilibration 279 
phase where water molecules position were restrained, then unrestrained systems were simulated 280 
for a total of 5 microseconds, in a NPT ensemble; Langevin equilibration scheme and Berendsen 281 
thermostat were used to keep constant temperature (300 K) and pressure (1 atm), respectively. 282 
Electrostatic forces were evaluated by Particle Mesh Ewald method and Lennard-Jones forces by 283 
a cutoff of 10 Å. All bonds involving hydrogen atoms were constrained using the SHAKE 284 
algorithm. Structural and graphical representations were carried out using VMD and prepared in 285 
Maestro (51). Simulations were run for 200 ns in each system. 286 
 287 
Blot overlay 288 
Recombinant PP1γ2 protein was resolved by SDS-PAGE and transferred onto a nitrocellulose 289 
membrane that was incubated with either recombinant AKAP4 protein (25 pmol/mL) (ab152924, 290 
Abcam, Cambridge, MA, USA) or MSS1 peptide (500 pmol/mL) and recombinant AKAP4 291 
protein (25 pmol/mL) (ab152924, Abcam, Cambridge, MA, USA). After washing to remove 292 
excess protein, bound AKAP4 was detected by incubating the membrane with a mouse anti-293 
AKAP4 antibody (ab56551, Abcam, Cambridge, MA, USA). Immunoreactive bands were 294 
revealed by incubation with an Infrared IRDye-labeled anti-mouse secondary antibody using the 295 
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Odyssey Infrared Imaging System (LI-COR Biosciences, US). Ponceau S was used as the protein-296 
loading control. 297 
 298 
Co-immunoprecipitation of biotinylated PP1γ2-CT peptide in human spermatozoa 299 
To identify the interactome of the unique C-terminus of PP1γ2 in human spermatozoa, a co-300 
immunoprecipitation of the biotinylated PP1γ2-CT peptide was performed.  15 x 106 human sperm 301 
cells were incubated with 5 µM of biotinylated PP1γ2-CT peptide for 15 min at 37°C in a 302 
humidified atmosphere of 5% CO2. Negative controls contained no peptide.  Sperm cells were 303 
collected by centrifugation (600g for 15 min) and lysed in 250 µl of 1x RIPA buffer (0.5M Tris-304 
HCl, pH 7.4, 1.5M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA) (Millipore Iberica 305 
S.A.U., Madrid, Spain) supplemented with protease inhibitor (1 mM PMSF) for 30 minutes on 306 
ice and centrifuged at 16000g for 15 min at 4ºC. 90% of the supernatant (sperm soluble fraction) 307 
was used for the subsequent steps. 10% of the soluble fraction was saved and the pellet (sperm 308 
insoluble fraction) was re-suspended in 250 µl 1% SDS. 50 µl of Dynabeads® M-280 Streptavidin 309 
(Life Technologies AS., Madrid, Spain) were added to the RIPA supernatant extracts and 310 
incubated for 30 min at room temperature with gentle rotation. After incubation, the supernatant 311 
was removed to a new tube and stored (unbound IP fraction). The beads were washed three times 312 
with 1 ml trypsin digestion buffer (20 mM Tris-HCl pH 8.0, 2 mM CaCl2) (for LC-MS/MS). After 313 
washing, the beads were re-suspended in 150 µl trypsin digestion buffer (20 mM Tris-HCl pH 314 
8.0, 2 mM CaCl2) and stored at -20°C until intensity-based label-free quantitative (LFQ) LC-315 
MS/MS analysis.  The experiment was performed in triplicate. 316 
 317 
Sample preparation and LC-MS/MS analysis 318 
A total of 6 samples were prepared for LC-MS/MS analysis. Washed beads were re-suspended in 319 
150 µl digestion buffer and incubated for 4 h with 1 µg trypsin (Promega) at 37 ˚C. Beads were 320 
removed, another 1 µg of trypsin was added and proteins were further digested overnight at 37 321 
˚C. Peptides were purified on Omix C18 tips (Agilent), dried and re-dissolved in 20 µl loading 322 
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solvent A (0.1% trifluoroacetic acid in water/acetonitrile (ACN) (98:2, v/v)) of which 2 µl was 323 
injected for LC-MS/MS analysis on an Ultimate 3000 RSLCnano system (Thermo) in line 324 
connected to a Q Exactive mass spectrometer (Thermo). Trapping was performed at 10 μl/min 325 
for 4 min in loading solvent A on a 20-mm trapping column (made in-house, 100-μm internal 326 
diameter (I.D.), 5-μm beads, C18 Reprosil-HD, Dr. Maisch, Germany) and the sample was loaded 327 
on a 150-mm analytical column (made in-house, 75-μm I.D., 3-μm beads C18 Reprosil-HD, Dr. 328 
Maisch). The Ultimate 3000’s column oven was set to 35°C. For proper ionization, a fused silica 329 
PicoTip emitter (10 µm inner diameter, New Objective) was connected to the analytical. Peptides 330 
were eluted by a linear increase from 2 to 55% MS solvent B (0.1% FA in water/ACN (2:8, v/v)) 331 
over 120 min, at a flow rate of 300 nl/min, followed by a 5-miN washing phase plateauing at 99% 332 
MS solvent B and a re-equilibration phase for 32 min with 98% MS solvent A (0.1% FA in water) 333 
adding up to a total run length of 160 min. The mass spectrometer was operated in data-dependent, 334 
positive ionization mode, automatically switching between MS and MS/MS acquisition for the 5 335 
most abundant peaks in a given MS spectrum. The source voltage was 4.5 kV, and the capillary 336 
temperature was 275°C. One MS1 scan (m/z 400−2,000, AGC target 3 × 106  ions, maximum ion 337 
injection time 80 ms), acquired at a resolution of 70,000 (at 200 m/z), was followed by up to 5 338 
tandem MS scans (resolution 17,500 at 200 m/z) of the most intense ions fulfilling predefined 339 
selection criteria (AGC target 5 × 104 ions, maximum ion injection time 80 ms, isolation window 340 
2 Da, fixed first mass 140 m/z, spectrum data type: centroid, underfill ratio 2%, intensity threshold 341 
1.3 x 104, exclusion of unassigned, 1, 5-8, >8 positively charged precursors, peptide match 342 
preferred, exclude isotopes on, dynamic exclusion time 12 s). The HCD collision energy was set 343 
to 25% Normalized Collision Energy and the polydimethylcyclosiloxane background ion at 344 
445.120025 Da was used for internal calibration (lock masses). 345 
 346 
LC-MS/MS data analyses 347 
Data analysis was performed with MaxQuant (version 1.5.7.4) using the Andromeda search 348 
engine with default search settings including a false discovery rate set at 1% on both the peptide 349 
and protein level. Spectra were searched against the SwissProt human database (from January 350 
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2017 with 20,172 entries). The mass tolerance for precursor and fragment ions was set to 4.5 and 351 
20 ppm, respectively, during the main search. Enzyme specificity was set to C-terminal of 352 
arginine and lysine, also allowing cleavage next to prolines with a maximum of two missed 353 
cleavages. Variable modifications were set to oxidation of methionine residues, phosphorylation 354 
of serine, threonine and tyrosine as wells as acetylation of protein N-termini. Matching between 355 
runs was enabled with a matching time window of 1 minute and an alignment time window of 20 356 
min. Only proteins with at least one unique or razor peptide were retained leading to the 357 
identification of 629 proteins. Proteins were quantified by the MaxLFQ algorithm integrated in 358 
the MaxQuant software. A minimum ratio count of two unique or razor peptides was required for 359 
quantification. Further data analyses were performed with the Perseus software (version 1.5.5.3) 360 
after uploading the protein groups file from MaxQuant. Reverse database hits were removed and 361 
replicate samples were grouped. Proteins with less than three valid values in at least one group 362 
were removed and missing values were imputed from a normal distribution around the detection 363 
limit resulting in 463 quantified proteins, which were subsequently used for further data analysis. 364 
These quantified proteins were subjected to a two-sided, unpaired t-test using permutation-based 365 
muliparameter correction with 1000 randomisations and a false discovery rate of 1%. The results 366 
of this t-test are shown in the volcano plot in Supplementary Figure 1 and listed in Supplemental 367 
Table 15. For each protein, the log2 (CT/NCT) fold change value is indicated on the X-axis, while 368 
the statistical significance (-log p value) is indicated on the Y-axis. Proteins outside the curved 369 
lines, set by an FDR value of 0.01 and an S0 value of 1 in the Perseus software, represent specific 370 
PP1γ2-CT interaction partners. 371 
 372 
Bioinformatic Analysis: Gene Annotation and Involvement in Male Infertility-Related 373 
Phenotypes 374 
The UniProt database was used to collect information regarding molecular function and the 375 
Human Protein Atlas (HPA) database (available from www.proteinatlas.org) was used to retrieve 376 
information regarding tissue expression and subcellular location (data was downloaded on 377 
23/01/2020). The databases DisGeNET (curated gene-disease associations list downloaded on 378 
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06/2019) and Disease (data downloaded on 06/2019) were explored to identify proteins associated 379 
with male infertility phenotypes. Proteins associated with defects in male fertility were also 380 
obtained from the Jackson Laboratories mouse knockout database - MGI (data downloaded on 381 
06/2019). The HIPPIE database was used for retrieving human PPI data (downloaded 07/2019). 382 
This database is regularly updated by incorporating interaction data from major expert-curated 383 
experimental PPI databases (such as Bell09, BioGRID, HPRD, IntAct, and MINT). Network 384 
analyses were performed using Cytoscape (version 3.6.0) (52) (Institute for Systems Biology and 385 
International Consortium of Open Source Developers, Seattle,Washington, USA). 386 
 387 
Statistical analyses 388 
Descriptive statistics of all data were calculated. To determine the in vitro effect of the bioportides 389 
on PP1 activity, for each condition (11 conditions), a Pos Hoc analysis of the Friedman test to 390 
detect differences over time (pairwise comparisons) was performed. For each time (0 m, 5 m, 15 391 
m, 20 m, 25 m and 30 m), the Kruskall Wallis test was used to detect differences between the 392 
conditions (independent groups). Finally, a pairwise comparison of conditions test was applied to 393 
identify between differences (Mann-Whitney U test). The statistical significance of the effect of 394 
the exposure of bioportides on human and bovine spermatozoa motility and vitality was calculated 395 
with Mann Whitney U-tests. The significance level was set at 0.05.   396 
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Results 397 
The AKAP4-BM bioportide translocates into spermatozoa to negatively impact upon 398 
spermatozoa motility 399 
A lead disruptive AKAP4-BM bioportide comprising the PP1 binding motif RVxF in AKAP4 400 
(40KVICF44) and flanking sequences was designed (Table 1). A bioportide with penta-alanine 401 
substituted for the PP1 binding motif of AKAP4 (AKAP4-BMmut) was used as control. 402 
Fluorescent microscopy confirmed the intracellular accumulation of both AKAP4-BM and 403 
AKAP4-BMmut bioportides within human (Figure 1 a) and bovine spermatozoa. Quantitative 404 
analyses demonstrated that, even at time zero, corresponding to the addition of the bioportides to 405 
spermatozoa and immediate washing to remove the bioportide containing solution, the AKAP4-406 
BM bioportide had entered the sperm cells (Figure 1 b). Intracellular accumulation of AKAP4-407 
BM increased with both time- and concentration-dependent kinetics (Figure 1 b). The intracellular 408 
uptake of AKAP4-BMmut did not increase over time and exposure to increasing concentrations 409 
of this bioportide revealed a saturation at 7.5 µM (Figure 1 b). These differences in uptake efficacy 410 
may be explained, at least in part, by an intact RVxF motif in AKAP4-BM specifically interacting 411 
with intracellular sperm proteins.  412 
The percentage of viable human spermatozoa was not significantly altered after treatment with 413 
10 μM bioportides, except by the 2h incubation with the AKAP4-BM bioportide where a decrease 414 
was observed (Figure 1 c and Supplementary Table 1; similar results were observed in bovine 415 
spermatozoa, Supplementary Table 3). A significant decrease in sperm vitality was observed at a 416 
20 μM exposure of the AKAP4-BM bioportide (Supplementary Table 3). 417 
Exposure of human sperm to AKAP4-BM bioportide induced a significant decrease in both fast 418 
and slow progressive motility and an increase in the percentage of immotile spermatozoa in 419 
comparison with both the negative control and the mutated bioportide (Figure 1 d ; Supplementary 420 
Tables 1 and 2; similar results were observed in bovine spermatozoa, Supplementary Tables 3 421 
and 4). There was no time-dependent effect of the AKAP4-BM bioportide in any motility 422 
parameter (Supplementary Table 4).  423 
 424 
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Computational studies of the AKAP4/PP1γ interaction enabled the design of an optimised 425 
bioportide 426 
To increase the potency of action of the AKAP4-BM bioportide, computational modelling studies 427 
were performed. First, the structural dynamics of protein target (PP1γ) was studied by means of 428 
all atom MD simulations to explore protein conformations and variations in the shapes of binding 429 
pocket on the surface of the target. The main conformations sampled by the protein in this 430 
timespan were characterized by cluster analysis. One major cluster, containing more than 90% of 431 
the structures, was identified. The representative structure of this cluster was then used as a target 432 
for further docking and peptide-design studies (Figure 1 e). Specifically, our attention was 433 
focused on the RVxF binding pocket, which is unique to PP1 within the phosphoprotein 434 
phosphatase-like and is the primary anchor point for most RIPPOs. RVxF features residues were 435 
161, 164, 237, 238, 250, 252, 256, 259, 261, 278, 283, 284, 286, 288, 290, 291. Root Mean Square 436 
Fluctuation (RMSF) analysis of the pocket indicates a high structural stability for this substructure 437 
(Figure 1 f).  438 
As no crystal structure of AKAP4 is available, we performed MD simulation based on part of the 439 
sequence of the AKAP4-BM bioportide (QRKVICFVAV - labeled here as AKAP4wt) to 440 
investigate its structural preferences. 500 ns simulation was carried out. The most representative 441 
cluster structure (35%) was retrieved for further docking. The representative structure of the most 442 
populated conformational cluster was used as target structure for docking. Next, the most 443 
favourable docking pose obtained from the previous docking experiment was used as a template 444 
to generate optimised sequences using the PinaColada (53) approach. Once an optimised 445 
sequence hypothesis was obtained, the latter was further refined using the PepCrawler algorithm 446 
(Donsky and Wolfson, 2011).  PepCrawler rapidly generates large amounts of flexible peptide 447 
conformations, allowing backbone and side chain flexibility. A binding energy funnel score was 448 
used to evaluate the protein–peptide complexes binding affinity. On this basis, we selected the 449 
best performer for further synthesis: AKAP4_Pep3: YRSVITFVAV (Figure 1 g; Supplementary 450 
Table 5). This approach enabled the design of an optimised Modified Stop Sperm (MSS1) 451 
bioportide, based on AKAP4_Pep3 (Table 1). 452 
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 453 
The MSS1 bioportide disrupts PP1γ2/AKAP4 interaction to significantly decrease 454 
spermatozoa motility 455 
The disruption of PP1γ2/AKAP4 interaction by the MSS1 bioportide was demonstrated by blot 456 
overlay. Recombinant PP1γ2 protein was resolved by SDS-PAGE and the membranes were 457 
incubated with either recombinant AKAP4 protein (25 pmol/mL) or MSS1 bioportide (500 458 
pmol/mL) plus recombinant AKAP4 protein (25 pmol/mL). After washing to remove excess 459 
protein, bound AKAP4 was detected by incubating the membrane with a mouse anti-AKAP4 460 
antibody. Increased quantities of recombinant PP1γ2 protein resulted in proportionately increased 461 
amounts of AKAP4 binding, thus demonstrating its specific interaction with AKAP4 (Figure 1 462 
h). Incubation with  the MSS1 bioportide reduced the amount of AKAP4 protein bound to PP1γ2 463 
(Figure 1 h). 464 
Exposure of human spermatozoa to MSS1 induced a significant decrease in both fast and slow 465 
progressive motility and an increase in the percentage of immotile spermatozoa in comparison 466 
with both the negative control and the mutated bioportide (Figure 1 i and j; Supplementary Tables 467 
6 and 7). No significant alterations were observed in non-progressive motility (Supplementary 468 
Table 7). Application of the mutated AKAP4-BM did not lead to significant differences in 469 
motility parameters in comparison with the negative control (Figure 1 i and j; Supplementary 470 
Table 7). There were no significant differences between the time points tested (15 min and 1h) at 471 
10 μM exposure in any motility parameter (Supplementary Table 7). The percentage of viable 472 
spermatozoa was not significantly changed after treatment with the MSS1 bioportide at the 473 
concentrations tested (Supplementary Table 6 and 7). A decrease in sperm vitality began to be 474 
observed with a 20 μM exposure of the MSS1 bioportide. 475 
 476 
PPP1R2 bioportide modulates PP1γ2 activity and spermatozoa motility 477 
To assess the disruptive capacity of peptides designed based on a potent PP1 inhibitor (PPP1R2) 478 
RVxF motif, PP1 activity was evaluated in the presence of PPP1R2 and the PPP1R2-BM or 479 
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PPP1R2-BMsc peptides. Figure 2 a shows that PPP1R2 inhibited PP1γ2 in a concentration 480 
dependent manner (PPP1R2 alone does not present any phosphatase activity (data not shown)). 481 
After 15 min incubation PPP1R2 significantly inhibited approximately 50% of PP1γ2 activity, an 482 
effect that persisted up to at least 30 min incubation (Figure 2 a, Supplementary Table 8 and 9). 483 
Upon adding PPP1R2-BM, PP1γ2 activity was restored to original values starting at 15 min 484 
(Figure 2 a). PP1γ2 activity was also restored by PPP1R2-BMsc addition (time point 25 min and 485 
30 min) (Figure 2 a). These results prove that PPP1R2-BM bioportides disrupt the PP1γ2/PPP1R2 486 
complex, in vitro, and consequently restore PP1γ2 activity. 487 
Fluorescent cell imaging analysis revealed that fluorescently labeled PPP1R2-BM and PPP1R2-488 
BMsc (10μM) were able to translocate and accumulate in human and bovine sperm (Figure 2 b). 489 
Quantitative uptake comparisons demonstrated that PPP1R2-BM presents a higher cellular 490 
uptake, when compared with PPP1R2-BMsc (human 2.9 times; bovine 10.7 times) (Figure 2 c). 491 
Between human and bovine spermatozoa the accumulation pattern of both bioportides is similar. 492 
Higher concentrations were also analysed (20μM and 50 μM) and the pattern of bioportide 493 
distribution was similar (data not shown). 494 
Concerning the effect of PPP1R2-BM on sperm motility, exposure of bovine sperm to 100 μM 495 
PPP1R2-BM reduced significantly the percentage of progressive fast motile sperm at 1 h and 2 h 496 
compared with the negative control (Figure 2 e). In contrast, the percentage of immotile sperm 497 
increased significantly in both timepoints tested (Figure 2 e, Supplementary Table 10 and 11). 498 
PPP1R2-BMsc presented a similar effect (Figure 2 e). No significant alterations were observed 499 
in slow progressive motility, non-progressive motility and vitality (Figure 2 d; Supplementary 500 
Table 11). 501 
 502 
Computational studies of the PPP1R2-BM bioportides 503 
Molecular dynamics simulations were performed with the PPP1R2-BM peptide sequence, which 504 
comprised the PPP1R2 RVxF binding motif and 7 AA flanking at N- and C-termini. Figure 2 f 505 
and e shows that the RVxF binding motif forms a rigid secondary structure, an α-helix, while the 506 
 22 
remaining sequence showed no secondary structure. In the case of PPP1R2-BM peptide, the most 507 
frequent cluster presented a pronounced α-helix at the N-terminus and a tendency to form a α-508 
helix at the C-terminus. The middle region, comprising the scrambled RVxF binding motif 509 
(QWKKSD), showed no evident secondary structure with an apparently higher flexibility (Figure 510 
2 f and g). Next, AA substitution studies using previous crystallography studies (PDB code 2O8G) 511 
revealed that the peptide with PPP1R2 RVxF scrambled may bind more stably and with more 512 
affinity with the core region of the PP1 RVxF pocket. The substitution of lysine to a glutamine in 513 
the first AA of RVxF motif appears to provide more stability to the peptide, while the change in 514 
the second AA from a serine to a tryptophan confers more affinity to the PP1 RVxF pocket (Figure 515 
2 h). In view of these results, it is possible to envisage that a higher degree of structural 516 
preorganization correlates with better observed activity. 517 
 518 
The PP1γ2-CT bioportide translocates into spermatozoa with a negative impact on motility 519 
A peptide sequence that mimics the unique 22-amino acid C-terminus of PP1γ2 (PP1γ2-CT) and 520 
is conserved in both bovine and human proteins was used to compromise the isoform-specific 521 
interactions between PP1γ2 and its interactors. 522 
Fluorescent microscopy revealed the intracellular accumulation of the PP1γ2-CT bioportide in 523 
human (Figure 3 a) and bovine spermatozoa. Quantitative analysis demonstrated that at time zero, 524 
corresponding to the addition of the bioportides and immediate washing to remove the bioportide 525 
containing solution, the PP1γ2-CT bioportide had already entered sperm cells, revealing its rapid 526 
intracellular translocation (Figure 3 b). Additionally, bioportide uptake increased over time 527 
(Figure 3 b). Exposure of spermatozoa to increasing concentrations of the PP1γ2-CT bioportide 528 
was followed by increasing intracellular translocation (Figure 3 b).  529 
The percentage of viable spermatozoa, both human and bovine, was not significantly changed 530 
after treatment with the bioportide (Figure 3 c; Supplementary Table 12 and 13). Exposure of 531 
human spermatozoa to PP1γ2-CT induced a significant decrease in both fast and slow progressive 532 
motility and an increase in the percentage of immotile spermatozoa (Figure 3 d and e; 533 
 23 
Supplementary Table 2 and 12). Similar results were observed in bovine spermatozoa 534 
(Supplementary Table 14). No significant alterations were observed in non-progressive motility 535 
in both bovine and human samples (Supplementary Table 2 and 14). There were no significant 536 
differences between the concentrations tested (5, 10 and 20 μM) in any motility parameter 537 
(Supplementary Table 14). Moreover, there was no time-dependent effect on motility of the 538 
PP1γ2-CT bioportide for the conditions tested (Supplementary Table 14). Both PP1γ2-CT and 539 
TAMRA- PP1γ22-CT induced a similar effect on sperm motility parameters, revealing that the 540 
fluorescent labelling did not affect significantly the peptide’s action (Supplementary Table 14).  541 
 542 
PP1γ2 C-terminus interactome 543 
To identify proteins that specifically interact with the 22-amino acid C-terminus of the human 544 
PP1γ2, human spermatozoa were incubated with a biotinylated PP1γ2-CT (B-PP1γ2-CT) 545 
bioportide and a co-immunoprecipitation of the peptide was performed followed by LC-MS/MS 546 
analyses. Two peptides that matched with the PP1γ2-CT peptide sequence were identified 547 
(Supplementary Table 15) which indicates bait recovery after pull down. No peptides 548 
corresponding to PP1γ2-CT were identified in the negative control. 549 
Mass spectrometric data revealed 73 proteins upregulated in samples incubated with the peptide 550 
when compared with the negative controls (Supplementary Table 16). Interactors were identified 551 
using a student’s t-test comparing the LFQ intensities of all proteins identified in replicates of CT 552 
with the LFQ intensities of all proteins identified in the control. Proteins were classified as 553 
interactors according to their position in the volcano plot. When log2(CT/NC) and -log(p-value) 554 
were plotted against each other in a volcano plot the unspecific background binders appears 555 
around zero. The interactors appear on the right side of the volcano plot and the higher the 556 
difference between the group means and the p value the more the interactors move to the top right 557 
corner of the plot, which is the area of highest confidence for a true interaction. Among these 73 558 
proteins, 23 proteins were classified as possible contaminants and consequently excluded (e.g. 22 559 
ribosomal proteins and one extracellular matrix glycoprotein). Previous findings indicate that 560 
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ribosomal proteins have high affinity to the magnetic beads (54). Only proteins that were 561 
quantified in at least 3 replicates of one of both conditions were considered. 562 
Thus, we identified 50 proteins that interact with the 22-amino acids C-terminus of human PP1γ2 563 
(Supplementary Table 16).  564 
 565 
Network of the PP1γ2 C-terminus interactome 566 
A protein-protein interaction (PPI) network was constructed with the proteins identified as PP1γ2-567 
CT interactors (Figure 3 f). The total number of proteins in the PPI network is N=50 and the total 568 
number of interactions between them is L=36. Twenty-two proteins from the dataset had no PPI 569 
data available (isolated nodes). In Figure 3 f, node size is proportional to the number of 570 
interactions of each node (k, degree). CUL3 (k=11), YBX1 (k=11), and CSNK1A1 (k=4) were 571 
the proteins with higher degree of connectivity in the network. Not considering the isolated nodes, 572 
the average number of neighbours in the network was 2,571. The mean clustering coefficient was 573 
C=0,247. The clustering coefficient characterizes how nearest neighbouring nodes of a node are 574 
connected to each other. If all of them are tightly connected to each other, then they form a clique 575 
and the clustering coefficient is 1. For a sparse random uncorrelated network of finite size N, this 576 
coefficient is close to zero. Note that the value C=0,247 is about 10 times larger than the clustering 577 
coefficient expected for a sparse random uncorrelated network (in the latter case C = <q>/N ~ 578 
0.02).  579 
Twenty-nine proteins identified as PP1γ2-CT interactors presented PP1-binding motifs (purple 580 
outline in Figure 3 f; Supplementary Table 17) and 10 are testis/sperm-enriched/specific proteins 581 
(square nodes in Figure 3 f). All proteins, except PUSL1 and YBX3 were previously identified in 582 
human sperm proteomes (compiled by (55)). Fifteen proteins (YBX2, YBX3 H1FNT, SEMG1, 583 
PRSS37, HIST1H2BA, PSME4, SEMG2, ACR, GPX4, PPP1CC, SERPINA5, PA2G4, ZPBP2 584 
and KLHL10) were associated with male infertility phenotypes. Twelve proteins were previously 585 
reported as involved in sperm motility regulation (blue nodes in Figure 3 f) and 3 in sperm-egg 586 
recognition and binding of sperm to zona-pellucida (pink nodes in Figure 3 f).  587 
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Discussion 588 
It is known that reversible protein phosphorylation is essential for sperm motility and that PP1 is 589 
a key player in this process (7,10,11). High PP1 activity is inversely correlated with sperm 590 
motility such that inhibition of PP1 catalytic activity results in motility initiation in immotile 591 
sperm and increased kinetic activity of motile sperm (10,11). PP1 catalytic activity, substrate 592 
specificity and subcellular localization are controlled by myriad regulatory subunits (RIPPOs). 593 
One of the major set-backs for the design of selective modulators for PP1 lies in the similarity of 594 
the catalytic pocket between PP1 and other serine/threonine phosphatases (29). A more attractive 595 
approach to modulate sperm motility is to target the interaction interfaces between PP1 and 596 
RIPPOs using disruptive peptides. In 1997, Egloff and colleagues, used a short peptide based on 597 
the RIPPO p53BP2 to disrupt PP1/PPP1R2 interaction in vitro (56) and Chatterjee and colleagues 598 
showed that peptides based on the RVxF motif can, in vivo, release PP1 from several interactors 599 
and restore PP1 activity (29). More recently, treatment of human diseased myocardium with a 600 
PP1 disrupting peptide was shown to had an antiarrhythmic effect (57). 601 
In this study, we demonstrated that a peptide which mimics the PP1 binding motif RVxF in 602 
AKAP4, a sperm-specific RIPPO, and its flanking sequences covalently coupled to penetratin 603 
(AKAP4-BM bioportide) was successfully delivered to sperm cells to significantly decrease 604 
sperm motility (Figure 1). Molecular modelling studies of the PP1/AKAP4 interaction facilitated 605 
the identification of the AKAP4-mimetic sequence YRSVITFVAV as an optimized binding 606 
sequence and enabled the development of an optimized Modified Stop Sperm (MSS1) bioportide 607 
with reduced size and increased potency of action (Figure 1; Table 1). The ability of MSS1 to 608 
disrupt the PP1γ2/AKAP4 complex in vitro confirmed a dominant-negative mode of action of this 609 
bioportide (Figure 1). 610 
To further corroborate the general utility of the bioportide technology in modulating sperm 611 
motility, we also designed a bioportide to mimic the pentapetide PPP1R2 RVxF binding site 612 
(KSQKW) and flanking 7 AA sequences. This 19AA sequence was covalently coupled to the 613 
C105Y CPP to affect delivery into the sperm flagellum. In vitro studies proved that PPP1R2-BM 614 
bioportide disrupted PP1γ2/PPP1R2 interaction restoring PP1γ2 activity (Figure 2). Also, the fact 615 
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that half the amount of PPP1R2-BM released PP1γ2 from PPP1R2 inhibition suggests that the 616 
peptide has a high affinity towards PP1γ2 RVxF pocket. These results indicate that PPP1R2-BM 617 
competitively binds to PP1, displacing PPP1R2 and thereby increasing PP1γ2 activity. 618 
Surprisingly, the scrambled PPP1R2-BMsc bioportide also restored PP1γ2 activity (Figure 2). 619 
PPP1R2-BMsc presents a scrambled RVxF motif (QWKKS) which computational studies 620 
revealed to result in a higher structural stability and affinity towards the PP1 RVxF pocket. This 621 
unexpected finding explains the observed biological effect of this scrambled bioportide (Figure 622 
2). Both PPP1R2-BM and PPP1R2-BMsc significantly decreased the percentage of fast motile 623 
sperm with a corresponding and increase in the percentage of immotile sperm (Figure 2).  624 
Although PP1 isoforms typically display similar functional properties, the fact that they are 625 
differentially expressed and have a specific set of protein interactors hints that they can perform 626 
distinct and cell-type specific functions. This feature is evident in PP1γ isoform knockout studies, 627 
where the expression of other PP1 isoforms can compensate for the absence of PP1γ in every 628 
tissue except for the testis, rendering males infertile (13). More recently, it was confirmed that 629 
the spermatogenic defects observed in the global Ppp1cc knockout mice were specifically due to 630 
compromised PP1γ2 function (14,58) and that transgenic PP1γ1 expression and absence of PP1γ2 631 
in Ppp1cc null mice, resulted in normal spermatogenesis but PP1γ2 was required for normal 632 
sperm function, specifically sperm motility (59). Specifically, the sperm localization of PP1γ1 in 633 
the transgenic mice and the association with RIPPOs were altered (59). Here we showed that a 634 
peptide that mimics the unique 22-amino acid C-terminus of PP1γ2 coupled with a CPP was able 635 
to penetrate the sperm cell to significantly decrease sperm motility (Figure 3). We hypothesize 636 
that the PP1γ2-CT peptide competes with isoform-specific interactors potentially involved in the 637 
targeting/inhibition of this phosphatase, affecting its action and, consequently, spermatozoa 638 
motility. Endophilin B1t, a testis enriched isoform of the somatic endophilin B1a, and the 639 
spermatogenic zip protein (Spz1) represent two PP1γ2 isoform-specific interactors previously 640 
identified (60,61). Both endophilin B1t and Spz1 do not interact with other PP1 isoforms or with 641 
a truncated PP1γ2 mutant lacking the unique C-terminus. Endophilin B1t and Spz1 were 642 
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previously shown to specifically inhibit PP1γ2 isoform activity (60,61). As stated previously, PP1 643 
inhibition is essential for sperm motility. To identify other PP1γ2-specific interactors and 644 
elucidate the mechanism of action of PP1γ2-CT bioportide in inhibiting sperm motility, the 645 
interactome of the PP1γ2-CT bioportide was performed in human spermatozoa. Of the 50 PP1γ2-646 
CT interactors identified by LC-MS/MS, 12 were identified as associated with regulation of sperm 647 
motility (blue nodes in Figure 3 f). Additionally, PP1γ2 localization in the sperm equatorial region 648 
suggests a role in sperm-egg interaction. In fact, TMEM225, a protein predominantly localized to 649 
the equatorial segment in mature spermatozoa of mice, was previously  described as an interactor 650 
and inhibitor of  PP1γ2 (62). Here we identified 3 proteins as PP1γ2-CT interactors that are 651 
involved in sperm-egg recognition and binding of sperm to zona-pellucida (pink nodes in Figure 652 
3 f).  653 
In conclusion, these studies indicate that proteomimetic bioportides can enter endocytosis-654 
incompetent human sperm cells to modulate the activity of the testis- and sperm-specific protein 655 
PP1γ2 and so reduce sperm motility, a key prognostic indicator of male fertility. Although a 656 
marked decrease on sperm motility was achieved, motility was not completely abolished. To 657 
completely abolish sperm motility, we believe a multi-interaction interface targeting approach 658 
can be undertaken by combining bioportides targeting the RVxF-binding site, such as MSS1, and 659 
a bioportide mimetic of the unique C-terminus of PP1γ2. Also, the biochemical optimisation of 660 
the bioportides is likely to generate more efficacious lead compounds for clinical evaluation. For 661 
instance, to improve the stability of the optimized MSS1 (YRSVITFVAV), residues flanking the 662 
SVITF binding motif could be substituted with non-natural isosteres and D-amino acids. Retro, 663 
inverso and retro-inverso strategies, common structural modifications of bioactive peptides, are 664 
equally compatible with bioportide technologies. Individually and collectively, such 665 
modifications are likely to enhance both the pharmacodynamic and pharmacokinetic properties 666 
of next-generation Stop Sperm bioportides. Given that CPPs demonstrate an inherent lack of 667 
target specificity, it is also necessary to employ strategies to achieve sperm-specific delivery for 668 
clinical applications (36). Phage display technologies have generated several high-affinity cell- 669 
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and tissue-Homing Peptides which can be incorporated into bioportides as N- or C-terminal 670 
extensions or via a flexible linker (63). The modular nature of the Stop Sperm peptides will 671 
facilitate the synthesis of chimeric sequences modified by the inclusion of sperm-selective 672 
homing sequences to enable targeting in vivo.  673 
  674 
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Table 1 - Designation, sequence and molecular masses of the bioportides designed in this study. 675 
Underlined are the CPPs, penetratin (RQIKIWFQNRRMKWKK) or C105Y 676 
(CSIPPEVKFNKPFVYLI); PP1 binding motif are in bold (pattern in AKAP4: [RK]-X(0,1)-[VI]-677 
{P}-[FW]; pattern in PPP1R2: K-S-Q-K-W). In italic are the RVxF flanking sequences. Peptide 678 
masses (M+ H+) were confirmed by MALDI time of flight mass spectrometry. To enable 679 
quantitative and qualitative uptake studies, peptides were extended with TAMRA fluorophore. 680 
1The last AA of PP1γ2 C-terminus (glutamic acid) was excluded due to its negative charge. All 681 





AKAP4-BM GQQDQDR40KVICF45VAVSTLNV53RQIKIWFQNRRMKWKK 4448.3 
AKAP4-BMmut GQQDQDR40AAAAA45VAVSTLNV53RQIKIWFQNRRMKWKK 4212.9 
PPP1R2-BM VDEELSK44KSQKW48DEMNILA54CSIPPEVKFNKPFVYLI 4239.0 
PPP1R2-BMsc VDEELSK44QWKKS48DEMNILA54CSIPPEVKFNKPFVYLI 4239.0 
PP1γ2-CT1 RQIKIWFQNRRMKWKKKPNATRPVTPPRVASGLNPSIQKASNYRNNTVLY 5953.0 




Figure 1 – Intracellular accumulation and  impact on human sperm vitality and motility of 
the AKAP4-BM bioportides and molecular dynamics simulations and impact of the MSS1 
bioportide in PP1γ2-AKAP4 complex and human sperm motility a) Microscopic evaluation 
of the intracellular accumulation of the AKAP4-BM bioportides in human spermatozoa: sperm 
cells were incubated for 1h with 10 μM TAMRA-labeled AKAP4-BM and AKAP4-BMmut (data 
not shown) and subsequently treated with 1% (w/v) trypsin. Negative control without the 
TAMRA-labeled peptides was performed and presented no reactivity (data not shown). Images 
are representative from three independent experiments. b) Quantitative analysis of AKAP4-BM 
and AKAP4-BMmut translocation into spermatozoa: sperm cells were incubated with TAMRA-
labeled peptides (5 µM) for the times indicated (left); Sperm cells were incubated with 5 µM, 7,5 
µM and 10 µM of TAMRA-labeled peptides for 15 min (right). Three independent experiments 
were performed in triplicated . Data are expressed as mean fluorescence (minus negative control). 
c and d) Impact of the peptides treatment (10 µM) in human sperm (c) vitality and (d) motility. 
Graph bars represent the mean values of three independent experiments performed in triplicate. 
Error bars 95% CI. Statistically significant findings are indicated with a (*). * P<0.05; ** P<0.01. 
e) 500 ns simulation of PP1γ protein. Snapshot of the predominant conformation cluster of MD 
simulation (90%) (grey), blue spheres indicate the RVxF binding pocket. f) RMSF showed high 
stability at the RVxF pocket residues161, 164, 237, 238, 250, 252, 256, 259, 261, 278, 283, 284, 
286, 288, 290, 291 (grey boxes). g) Superimposition of PP1γ-AKAP4-Pep3 complex retrieved 
from the best ranked result of PinaColada. h) Impact of the MSS1 bioportide in PP1γ2-AKAP4 
complex. PP1γ2 protein was resolved by SDS-PAGE and the membranes overlaid with either 
recombinant AKAP4 protein (25 pmol/mL) or MSS1 peptide (500 pmol/mL) and recombinant 
AKAP4 protein (25 pmol/mL). The binding was detected with anti-AKAP4 antibody. AKAP4 
fluorescent signal was normalized to Ponceau S. Graph bars represent the mean values of 3 
independent experiments. i and j) Impact of the MSS1 bioportide (10 μM) in human sperm 
motility. Graph bars represent the mean values of 3 independent experiments performed in 
 31 
triplicate. Error bars 95% CI. * p<0.05; ** p<0.01. NC, negative control; MF, mean fluorescence; 
AU, arbitrary units. 
Figure 2 – Effect of PPP1R2-BM bioportides towards disrupting PP1γ2/PPP1R2 complex, 
intracellular accumulation of the PPP1R2-BM bioportide in sperm, impact of PPP1R2-BM 
bioportide on sperm vitality and motility and molecular dynamics simulations on affinity 
and stability of PPP1R2-BM bioportide towards PP1 RVxF pocket. a) Comparison of 
phosphatase activity of PP1γ2 and PP1γ2/PPP1R2/PPP1R2-BM peptides. Data is expressed as 
arbitrary units of phosphatase activity (minus negative control). Graph bars and lines represent 
the mean values of 4 replicas. Error bars represent the SEM (standard error of the mean). 
Statistically significant findings are indicated with a (*). * P<0.05. b) Microscopic evaluation of 
the intracellular accumulation of the bioportides: sperm cells were incubated for 1h with 10 μM 
TAMRA-labeled peptides and subsequently treated with 1% (w/v) trypsin. Negative control 
without the TAMRA-labeled peptides was performed and presented no reactivity (data not 
shown). Images are representative from three independent experiments. c) Quantitative analysis 
of peptide translocation into human and bovine spermatozoa: sperm cells were incubated with 
TAMRA-labeled PPP1R2-BM or PPP1R2-BMsc (10µM) for 1h. The experiment was performed 
in triplicate in two different bulls or human samples. Data are expressed as mean fluorescence 
(minus negative control). Error bars represent the SEM (standard error of the mean). d-e) Impact 
of the-PPP1R2-BM peptides treatment (100 µM) in bovine spermatozoa (d) vitality and (e) 
motility. Graph bars represent the mean values of three independent experiments performed in 
triplicate. Error bars 95% CI. * P<0.05; ** P<0.01. NC, negative control. f) Molecular dynamics 
of PPP1R2-BM and PPP1R2-BMsc peptide. RVxF and the 7 flanking AA of the PPP1R2-BM 
peptide. g) Scrambled RVxF and the 7 flanking AA of the PPP1R2-BMsc bioportide. Note that 
the number of the AA correspond to their position within the peptide not within PPP1R2.  Green: 
N-terminus; Orange: C-terminus; Blue: RVxF AA side chains. h) AA substitution studies of 
RVxF motif. The substitutions studies were performed using previous experimental data on 
PP1/PPP1R2 interaction. The more negative the △affinity and △stability (kcal/mol), the stronger 
the affinity and stability, respectively. *In the scrambled peptide, the lysine present at position 47 
 32 
was not changed. In the substitutions studies this lysine was changed for an alanine. MF, mean 
fluorescence; AU, arbitrary units. 
Figure 3 – Intracellular accumulation of the PP1γ2-CT peptide in human sperm, impact on 
human sperm vitality and motility and protein-protein interaction network of the PP1γ2-
CT peptide. a) Microscopic evaluation of the intracellular accumulation of the PP1γ2-CT 
bioportide in human sperm: sperm cells were incubated for 1h with 10 μM TAMRA-labeled 
peptide and subsequently treated with 1% (w/v) trypsin. Negative control without the TAMRA-
labeled peptide was performed and presented no reactivity (data not shown). Images are 
representative from three independent experiments. b) Quantitative analysis of peptide 
translocation into spermatozoa: sperm cells were incubated with TAMRA-labeled PP1γ2-CT (5 
µM) for the times indicated (left); sperm cells were incubated with 5 µM, 7,5 µM and 10 µM of 
TAMRA-labeled PP1γ2-CT for 15 min (right). Three independent experiments were performed 
in triplicate. Data are expressed as mean fluorescence (minus negative control). c-e) Impact of 
the PP1γ2-CT bioportide treatment (10 µM) in human spermatozoa (c) vitality and (d and e) 
motility. Graph bars represent the mean values of three independent experiments performed in 
triplicate. Error bars 95% CI. Statistically significant findings are indicated with a (*). * P<0.05; 
** P<0.01. NC, negative control; MFI, mean fluorescence intensity; AU, arbitrary units. f) 
Protein-protein interaction network of the PP1γ2-CT peptide interactors. Purple outline 
represents proteins presenting PP1-binding motifs. Green nodes represent the proteins previously 
identified as PP1γ interactors. Blue nodes represent proteins associated with sperm motility. Pink 
nodes represent the proteins associated with sperm-egg recognition and binding of sperm to zona-
pellucida. Square nodes represent testis/sperm-enriched/specific proteins. Node sizes represent 
relative degree of the nodes. Proteins are represented by gene name. PP1γ (PPP1CC), shown in 
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